ACM
AKCA

Atika Capital Management’s Akcea Therapeutics Inc AKCA Stock Holding History

Atika Capital Management’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-90,000
Closed -$2.49M – 88
2017
Q3 		$2.49M Buy
+90,000
New +$1.67M 0.72% 55

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Atika Capital Management's AKCA Position: Q4 2017 in Review

Atika Capital Management sold out of Akcea Therapeutics Inc (AKCA) in Q4 2017, closing a stake of 90,000 shares — an estimated $2.49M sold.

Atika Capital Management first reported a position in AKCA in Q3 2017 and held it in 1 quarter. The position peaked at $2.49M in Q3 2017. 58 funds tracked by Wall St. Rank hold AKCA as of Q4 2017.

  • Atika Capital Management reported no remaining Akcea Therapeutics Inc position as of Q4 2017 after selling out during the quarter.
  • Atika Capital Management sold 90,000 Akcea Therapeutics Inc shares in Q4 2017, an estimated $2.49M.
  • Atika Capital Management first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 1 quarter.
  • Atika Capital Management's Akcea Therapeutics Inc position peaked at $2.49M in Q3 2017.
  • 58 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2017.

Based on Atika Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.